Clinical Trial Search

Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month

Primary: Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3 — -23.38; -31.33 hours/month — p=< 0.001

Primary: Headache Days — 23.64; 24.33 Days — p=0.83

Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants

Primary: Change in Migraine Characteristics — 43; 2; 17 Participants

Primary: The Percentage of Subjects in the Double-blind Period Who Are Pain Free at 2 Hours After Dosing as Reported by the Subject in the eDiary — 51.0; 30.8 Percentage of…

Primary: Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE) — 41; 151 Participants — p=<.001

Primary: Change From Baseline in Monthly Migraine Days at the Last Month (Month 3) of the Double-blind Treatment Period (DBTP) — -4.20; -4.79; -3.10 Migraine days/month — p=0.002

Primary: Change in Mean Headache Index Score Among Patients — -1.52 headache index score

Primary: Number of Participants Who Completed Initially Assigned Treatment and Achieved at Least a 50% Reduction From Baseline in Monthly Migraine Days at Month 12 — 232; 35…

Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants

Primary: Change From Baseline in Monthly Migraine Days at Week 12 — -2.28; -2.18; -2.39; -3.40 migraine days / month — p=0.021

Primary: Change From Baseline in Monthly Migraine Days (Weeks 1-12) — -4.3; -3.9; -4.1; -3.1 Migraine Days — p=0.0001

Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale

Primary: Number of Participants With Clinical Adverse Events (AEs) — 1582; 804 Participants

Primary: Placebo-controlled Period: Change From Baseline in the Number of MMDs at Weeks 1 - 4 — -6.85; -3.66 days/month — p=<0.0001

Primary: Percentage of Participants With 50% Response Rate Across the 3-month Treatment Period. — 62; 61 percentage of participants — p=0.695

Primary: Change in Number of Monthly Migraine Headache Days — -3.5; -1.1 migraine days

Primary: Number of Subjects With Pain Relief at 2 Hours From Time of First Dose — 136; 231 participants

Primary: Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period — -2.48; -3.69; -3.86; -4.20 migraine days per month — p=<.0001

Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03

Primary: Change From Baseline in Monthly Migraine Days at Week 12 — -1.84; -2.88 migraine days / month — p=< 0.001

Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. — -1.99; -3.81 days per month — p=<.0001

Primary: Headache Days in Each Treatment Period Month — 7.1; 10.88; 7.05; 9.47 Number of Headache days

Primary: Percent Change of Headache Days Compared to Baseline — -13.50; -36.50 percent change of headache days

Primary: Number of Migraine Attacks in Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate — 1.35; 2.12 Migraine attacks

Primary: Total Number of Responders — 17 Participants

Primary: Change From Baseline in the Number of Weekly Cluster Headache (CH) Attacks, Averaged Over Weeks 1-2 — -4.0; -4.6 Number of Weekly Attacks — p=0.5048

Primary: Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE) — 78.6; 67.0 percentage of participants

Primary: Reduction in Days of Headache Pain With Treatment of Memantine or Valproate in the Preventive Management of Episodic Migraine. — 5.35; 5.31; 0.77; 0.93 Migraine days by…